Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Formoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL17515075 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL29039567 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL4084169 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL31697543 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL29488544 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL82829 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL1650339 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL1660800 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3040814 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL3670606 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4514589-B1 | MOULD SYSTEM AND METHOD | PULPEX LTD (GB) | 2026-03-18 | — | — | EP | claimed |
| EP-4649960-A1 | USE OF LONG-ACTING ß2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | Hong Kong Sxmeterol Pharmaceutical Co., Limited (HK) | 2025-11-19 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| WO-2024160057-A1 | USE OF LONG-ACTING β2AR AGONIST IN PREPARATION OF DRUGS FOR TREATING CANCERS | 上海市第十人民医院 | 2024-08-08 | — | — | WO | claimed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| US-20240033232-A1 | New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome | TAN WEN (CN) | 2024-02-01 | — | — | US | claimed |
| EP-4255541-A1 | PRODUCT DELIVERY DEVICES AND METHODS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| US-20220270733-A1 | SYSTEMS AND METHODS FOR DETERMINING COMPLIANCE AND EFFICACY OF A DOSING REGIMEN FOR A PHARMACEUTICAL AGENT | SUMNER BLUFFS LLC (US) | 2022-08-25 | — | — | US | claimed |
| US-20220262507-A1 | PHARMACEUTICAL AND BIOLOGICAL AGENT DELIVERY SYSTEM HAVING BIOMETRIC DATA ACQUISITION AND MONITORING CAPABILITIES | SUMNER BLUFFS LLC (US) | 2022-08-18 | — | — | US | claimed |
| US-20220244247-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2022-08-04 | — | — | US | claimed |
| US-20220246263-A1 | NEBULIZING DEVICES AND SYSTEMS HAVING BIOMETRIC DATA ACQUISITION AND MONITORING CAPABILITIES | SUMNER BLUFFS LLC (US) | 2022-08-04 | — | — | US | claimed |
| WO-2022118220-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING RESPIRATORY DISORDERS | BREATHE RESTORE, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| US-20220168516-A1 | PRODUCT DELIVERY DEVICES AND METHODS | BREATHE RESTORE, INC. | 2022-06-02 | — | — | US | claimed |
| WO-2022109619-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220161969-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-26 | — | — | US | claimed |
| WO-2022074183-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-04-14 | — | — | WO | claimed |
| US-11298293-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | ADRB2 2053/4885ADRB1 2152/4885ADRB3 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.